JAZZ as reported
Jazz Pharmaceuticals plc reported $4.44B of revenue over the trailing twelve months, +9.2% on the year before. 11 reported series are charted on this page, each one as filed.
$4.44B
Revenue, trailing twelve months · to Q1 2026 · +9.2% against the twelve months before
- Net Income
- $29M
Net Income · −94% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $1.27B
Free Cash Flow · −16% year on year · trailing twelve months to Q1 2026
- Op Margin
- −1.9%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $4.44B | +9.2% | Q1 2026 |
| Net Income | $29M | −94% | Q1 2026 |
| EPS | $0.11 | −99% | Q1 2026 |
| Gross Margin | 93% | n/a | Q4 2020 · 21 quarters behind |
| Op Margin | −1.9% | n/a | Q1 2026 |
| Net Margin | −0.49% | n/a | Q1 2026 |
| ROE | −7.0% | n/a | Q1 2026 |
| ROA | −2.4% | n/a | Q1 2026 |
| ROIC | −3.1% | n/a | Q1 2026 |
| Free Cash Flow | $1.27B | −16% | Q1 2026 |
| P/E | 16.2 | n/a | Q1 2025 · 4 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Jazz Pharmaceuticals plc (JAZZ) - Revenue & ProfitRevenue & ProfitJazz Pharmaceuticals plc (JAZZ)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com